Skip to main content
Figure 1 | Respiratory Research

Figure 1

From: Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts

Figure 1

Effect of roflumilast and indacaterol on TGFβ1-induced ET-1 transcript (A, C) and protein (B, D) from NHLF. (A, C) NHLF were pretreated with compound or vehicle control for 1 h and RNA was made 6 h after TGFβ1 (10 ng/mL) treatment. Data represents the MFI normalized to HPRT1 and fold induction calculated versus non-stimulated control. All data represent mean ± SEM for n = 3 (A), and n = 8 (C) experiments, run in triplicate. (B, D) NHLF were pretreated with compound or vehicle control for 1 h and conditioned medium was collected 24 h after TGFβ1 (10 ng/mL) treatment and quantitated for ET-1 protein secretion. All data represent mean ± SEM for n = 3 (B), and n = 6 (D) experiments, run in triplicate. ROF: roflumilast, INDA: indacaterol. *p < 0.05, **p < 0.01, and ***p < 0.001 as compared to TGFβ1 vehicle-treated cells, ##p < 0.01 ###p < 0.001 as compared to roflumilast treated cells, &p < 0.05 as compared to indacaterol treated cells.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us